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ABSTRACT 
Pim kinases are upregulated in several forms of cancer, contributing to cell survival and 
tumour development, but their role in platelet function and thrombotic disease has not been 
explored.  
We report for the first time that Pim-1 kinase is expressed in human and mouse platelets. 
Genetic deletion or pharmacological inhibition of Pim kinase results in reduced thrombus 
formation but is not associated with impaired haemostasis. Attenuation of thrombus formation 
was found to be due to inhibition of the thromboxane A2 receptor as effects on platelet function 
was non-additive to inhibition caused by the cyclooxygenase inhibitor indomethacin or 
thromboxane A2 receptor antagonist GR32191. Treatment with Pim kinase inhibitors caused 
reduced surface expression of the thromboxane A2 receptor and resulted in reduced 
responses to thromboxane A2 receptor agonists, indicating a role for Pim kinase in the 
regulation of thromboxane A2 receptor function. 
Our research identifies a novel, Pim kinase dependent regulatory mechanism for the 
thromboxane A2 receptor and represents a new targeting strategy that is independent of COX-
1 inhibition or direct antagonism of the thromboxane A2 receptor that whilst attenuating 
thrombosis does not increase bleeding. 
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INTRODUCTION 
The family of Pim (proviral insertion in murine lymphoma) kinases, Pim-1, -2, and -3 are highly 
homologous serine/threonine kinases that are widely expressed across several cell types, and 
are expressed highly in haematopoietic cells. Pim kinases are constitutively active and are 
linked with cancer progression 1,2, with over-expression and upregulation of Pim kinase activity 
associated with both haematological and solid tumour cancers. They function by 
phosphorylating their target proteins on serine/threonine residues located within the common 
consensus sequence ARKRRHPS*GPPTA 1. A number of proteins that have important roles 
in the regulation of cellular proliferation and survival have been identified as phosphorylation 
targets of the Pim kinases 3-6. Expressed as a short (32 kDa) or long (44 kDa) variant, the 
longer variant of Pim-1 kinase, Pim-1L, kinase has also been found to regulate adenosine 
triphosphate-binding cassette (ABC) drug transporters 7-9. Pim-1 phosphorylates both 
BCRP/ABCG2 and Pgp transporters enabling, through different mechanisms, the formation of 
drug efflux pumps 7,9.   
Pim kinases are highly expressed in hematopoietic cells where they are important for 
differentiation and development of blood cells and blood cell precursors including 
megakaryocytes 10 and platelets 11. Whether Pim kinases are involved in the regulation of 
platelet function has not been explored. Analysis of the mouse megakaryocyte transcriptome 
database 12 identified multiple tags for both Pim-1 and Pim-2 kinases and the mRNA 
transcripts for all three Pim kinases have been identified in the human platelet transcriptome 
13,14. Interestingly although triple knock-out mice deficient in all three Pim kinase isoforms are 
viable, they have been shown to have altered haematopoiesis, but there is some dispute as 
to whether disruption of all three isoforms results in alteration of platelet count 10,11, however, 
platelet counts appear to be unaffected by alteration of Pim-1 expression levels in mice 15,16.  
Platelets rely on G protein coupled receptors (GPCRs) such as the Thromboxane A2 receptor 
(TPαR), ADP receptors (P2Y1 and P2Y12) and the thrombin receptors (PAR1 and PAR4) to 
mediate platelet activation in response to vessel damage. All platelet GPCRs are regulated in 
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some way by receptor cycling/internalisation from the platelet surface as well as 
desensitisation 17. Pim-1 kinase has also been shown to have a role in the regulation of G 
protein coupled receptor (GPCR) function, through modulation of surface levels of the CXCR4 
receptor 18,19. Inhibition of Pim kinase prevents Pim kinase dependent phosphorylation of 
CXCR4 at Ser339 and modification of the CXCR4 intracellular C terminal domain resulting in 
reduced surface expression and signalling.  In this study we report the presence of Pim-1 in 
human and mouse platelets, and reduced thrombosis in Pim-1 null mice, and following 
pharmacological inhibition of Pim kinase, but with no associated effect on haemostasis. We 
describe a novel mechanism of action by which Pim kinase inhibitors negatively regulate 
thromboxane A2 receptor (TPαR) signalling.  
 
METHODS 
Procedures and experiments using human blood were approved by the University of Reading 
Research Ethics Committee and protocols using mice were performed according to the 
National Institutes of Health and Medical College of Wisconsin Institutional Animal Care and 
Use Committee guidelines and as following procedures approved by the University of Reading 
Research Ethics Committee. 
Platelet isolation, thrombus formation assays, tail bleeding experiments, platelet function tests, 
aggregometry, granule secretion, flow cytometry, calcium imaging, immunoblotting, image 
analysis, statistical analyses and materials used are described in Supplemental Methods. 
 
RESULTS 
Expression of Pim kinase in human and mouse platelets 
Pim kinases are highly expressed in hematopoietic cells 10,11. mRNA transcripts for all three 
Pim kinases have been identified in the human and mouse platelet transcriptomes 13,14 and 
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HaemAtlas mRNA expression profiles in haematopoetic cells 20 show high expression of Pim-
1 in megakaryocytes and moderate expression in platelets (Figure 1 and Supplemental Figure 
1) 21.Western blot analysis of platelet lysates identified a protein band of 44kDa apparent 
molecular mass in both human and mouse platelet lysates indicating the expression of the 
larger Pim-1 variant (Pim-1L). A protein band at 32 kDa in mouse platelets also suggested 
expression of the smaller Pim-1S. K562 and Jurkat cell lines were included as positive controls 
8,18,22  (Figure 1B).  
Reduced thrombus formation in Pim-1 deficient mice 
To determine whether Pim-1 plays a role in the regulation of platelet function and thrombosis, 
we measured the ability of Pim-1 deficient mouse platelets taken from constitutive Pim-1 
deficient mice to form thrombi on collagen under arterial flow in vitro. Constitutive Pim1–/– mice 
were as described previously 15,16 and global deletion of Pim-1 confirmed by PCR analysis of 
genomic DNA (supplemental figure 2A). Mouse whole blood from Pim-1-/- or Pim-1+/- mice was 
perfused over collagen-coated (100 μg/mL) Vena8 biochips for 4 minutes at an arterial shear 
rate of 1000 s-1. Thrombus formation was significantly attenuated in blood from Pim-1-/- mice 
compared to controls, indicating Pim-1 plays a positive role in the regulation of platelet function 
and thrombus formation on collagen (Figure 2A). Constitutive Pim-1-/- mice show unaltered 
platelet counts and no difference in expression levels of major platelet adhesion receptors 
GPIbα, GPIbβ, GPIX, GPV, GPVI and integrins β1 and β3 was observed in Pim-1-/- platelets 
compared to controls (supplemental figure 2B). Interestingly, despite the reduced ability to 
form thrombi, Pim-1 deficient mice showed no alteration in haemostasis as tail bleeding was 
unaffected compared to littermate controls (Figure 2B).   
Pim kinase inhibitors reduce thrombus formation but do not disrupt haemostasis. 
As genetic deletion of Pim-1 in mice resulted in reduced in vitro thrombus formation, we 
assessed the effects of the Pim kinase inhibitor AZD1208 (100 µM) on thrombus formation in 
human whole blood. The effect of the Pim kinase inhibitor AZD1208 (100 µM) on thrombus 
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formation on collagen in human whole blood in vitro was also assessed. Human whole blood 
was pre-incubated with vehicle control or AZD1208 and perfused over collagen-coated (100 
μg/mL) Vena8 biochips at either an arterial shear rate (20 dynes/cm3 for 10 mins) or 
pathological shear rate (135 dynes/cm3 for 5 mins). Similar to that observed in Pim-1 deficient 
mice, a reduction in thrombus formation and stability on collagen under flow in vitro was also 
observed following AZD1208 treatment in comparison to vehicle treated controls under arterial 
shear conditions (figure 2C). Whilst thrombus size and stability appeared reduced at arterial 
flow rates, the early stages of thrombus formation, including initial adhesion, appeared 
unaffected by AZD1208 treatment. This is further supported by lack of inhibition of platelet 
adhesion and spreading on collagen by AZD1208 under static conditions (supplemental figure 
3), indicating that the initial adhesion to collagen is not affected by Pim kinase inhibition. 
Interestingly, enhanced inhibition of thrombus formation on collagen was observed following 
treatment with AZD1208 at pathological shear rates (~80% inhibition) Figure 2D) in 
comparison to the inhibition observed at arterial shear (~50% inhibition). In contrast to arterial 
and pathological shear rates, a slight (but not significant) reduction in thrombus formation was 
observed in AZD1208 treated platelets compared to vehicle treated controls under venous 
shear conditions (Figure 2E). Inhibitor treated platelets appeared to form ‘woolly’ or ‘loose’ 
aggregates compared to vehicle controls, but no difference in fluorescence intensity of 
platelets adhered was observed. These findings indicate Pim kinase inhibition does not 
significantly alter platelet adhesion and thrombus formation at low shear rates compared to 
the effects observed at higher shear rates. To examine whether Pim kinase inhibition could 
regulate thrombosis in vivo, we performed intravital microscopy following ferric-chloride-
induced injury in mice pretreated with AZD1208 (100 µM) or vehicle control (Figure 2F). As 
with in vitro thrombus formation, treatment with AZD1208 resulted in a dramatic attenuation in 
the ability of platelets to form thrombi in vivo at the site of FeCl3 injury with significantly 
prolonged occlusion times observed in AZD1208 treated mice (1463 ± 37 secs) compared to 
vehicle treated controls (697 ± 72 secs). This supports a role for Pim kinase in the positive 
regulation of platelet function, and the anti-platelet properties of Pim kinase inhibitors. 
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Interestingly, despite the dramatic attenuation in the ability of platelets to form thrombi in vivo, 
as with genetic deletion, pharmacological inhibition of Pim kinase was not associated with 
altered haemostasis. Tail bleeding assays performed in mice indicated that treatment with 
AZD1208 (100 µM) did not cause any significant increase in bleeding (Figure 2G), suggesting 
that despite the observed inhibitory effect on thrombus formation, normal haemostasis is not 
compromised following inhibition or genetic deletion of Pim kinase.  
Pim kinase inhibitors reduce platelet aggregation  
To determine how Pim kinase plays a role in the regulation of platelet function, human washed 
platelets were pretreated for 10 minutes with a range of concentrations of the pan-Pim kinase 
inhibitor AZD1208 before stimulation with platelet agonists. As shown in Figure 3A-E pre-
treatment of platelets with AZD1208 inhibited aggregation stimulated by collagen (1 µg/mL) or 
the thromboxane A2 (TxA2) mimetic U46619 (0.3 µM). A slight inhibition was also observed in 
CRP-XL stimulated platelets (0.3 µg/mL). In contrast no inhibition of thrombin (0.03 U/mL) or 
ADP (10 µM) induced platelet aggregation was observed following treatment with increasing 
concentrations of AZD1208 (up to 10 µM). Treatment with four other structurally unrelated Pim 
kinase inhibitors PIM-447 (LGH-447), SGI-1776, SMI-4a and CX6258 inhibited platelet 
aggregation stimulated by both collagen or U46619 but not thrombin, recapitulating findings 
with AZD1208 and supporting a Pim kinase-dependent mode of action (Supplemental figure 
4).  
Pim kinases have been shown previously to play important roles in cell survival as Pim-2 is 
known to phosphorylate and inactivate Bcl-2-associated death promoter (BAD) 23. Inhibition of 
Pim kinase enables activation of BAD and initiation of apoptosis 5. If Pim kinase inhibitors 
activate apoptosis in platelets, this could cause the observed reduction in aggregation. To 
investigate whether Pim kinase inhibition triggers apoptosis in platelets, phosphatidylserine 
exposure (a marker of membrane flippage) was determined by measuring Annexin V binding 
by flow cytometry following treatment for 2 hr with AZD1208 or BCL-2 inhibitor ABT-263, an 
activator of apoptosis in platelets (Supplemental Fig 5A). ABT-263 treatment caused an 
8 
 
increase in Annexin V binding but no difference was observed in AZD1208 treated platelets 
compared to vehicle treated controls over following the same incubation time. Furthermore, 
caspase cleavage did not occur in platelets following 2 hr treatment with Pim kinase inhibitors: 
AZD1208 (10µM), SGI-1776 (10µM), SMI-4a (30µM) or CX6258 (10µM), but did occur 
following treatment with the BCL-2 inhibitor ABT-263 (Supplemental Figure 5B). Together 
these observations suggest that Pim kinase inhibition does not initiate platelet apoptosis.  
Pim kinase inhibitors reduce TxA2 mediated α-granule secretion and integrin activation 
Alpha granule secretion and activation of integrin αIIbβ3 are critical events in platelet activation 
that underpin platelet activation and aggregation. We investigated the effects of AZD1208 (10 
µM) on alpha granule secretion and αIIbβ3 activation by measuring surface P-selectin exposure 
and fibrinogen binding respectively. AZD1208 (10 µM) inhibited alpha granule secretion and 
integrin activation evoked by collagen, CRP-XL and U46619 compared to vehicle treated 
controls (supplemental Figure 6). This suggests that Pim kinase inhibitors inhibit aggregation 
by reducing both integrin activation and secretion of granule contents.  
Pim kinase inhibitors reduce platelet activation to GPVI via reduced TPαR signalling 
TxA2 is synthesised and released following platelet activation by several platelet agonists. It 
acts as a secondary mediator, boosting platelet responses to other agonists, and is essential 
for the amplification of platelet activation and thrombus formation. Further investigation of the 
inhibitory actions of AZD1208, identified significant inhibition of U46619 evoked aggregation 
with IC50 values < 10µM, concentrations similar to those achieved in plasma in patients taking 
AZD1208 24, following stimulation by low concentrations of U46619 (0.03-1 µM) (Figure 4A). 
In contrast the inhibitory activity of AZD1208 could be overcome at higher concentrations of 
U46619 (3, 10 µM). Collagen induced platelet activation is known to be dependent on the 
release of secondary mediators. To test whether the inhibition of collagen induced platelet 
aggregation by AZD1208 was a result of reduced activation of the TPαR, platelet aggregation 
to a range of collagen concentrations was measured following treatment with AZD1208 (10 
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µM). We performed the experiments in the presence or absence of indomethacin (10 µM), a 
cyclooxygenase (COX) inhibitor that prevents TxA2 synthesis, or TPαR antagonist GR32191 
(100 nM) to investigate if inhibition was additive.  As shown in Figure 4B, both indomethacin 
and GR32191 caused an inhibition of collagen-induced platelet aggregation, but this was not 
additive to the inhibition caused by AZD1208, suggesting that AZD1208 shares a common 
TPαR.-dependent mechanism. The inhibition observed in collagen stimulated platelets is likely 
due to the loss of TxA2 signalling, indicating that Pim kinase has a positive regulatory role in 
the regulation of TPαR signalling. Similar results were also observed following treatment with 
structurally unrelated Pim kinase inhibitors SGI-1776, PIM-447 (LGH447), SMI-4a and 
CX6258 in the presence or absence of indomethacin (Supplemental Figure 4D-G). In further 
support of this, we also observed that AZD1208 mediated inhibition of thrombus formation on 
collagen under flow occurred via a TPαR dependent mechanism, as indomethacin (10 µM) 
did not cause further inhibition of thrombus formation when combined with AZD1208 treatment 
(Figure 4C). In support of the effects of AZD1208 being mediated via Pim kinase, and a role 
for Pim kinase in the regulation of platelet TPαR signalling, platelets from Pim1-/- mice (red) 
displayed reduced fibrinogen binding following stimulation with U46619 (10 µM) or CRP-XL 
(10 µg/mL) but not following stimulation with thrombin (0.01 U/mL) compared to controls 
(black) (Figure 4D). 
Pim kinase inhibitors inhibit platelet function independently of COX1.  
The synthesis of TxA2 in platelets is dependent on activation of COX1 following platelet 
stimulation. To determine whether the inhibitory effects of Pim kinase inhibitors were due to 
altered COX activity, TxB2 levels (a marker of TxA2 release) were determined following 
stimulation of platelets with arachidonic acid (a direct substrate for COX-1 and the TxA2 
synthesis pathway) or collagen and compared to indomethacin, a COX1 inhibitor in the 
presence of TPαR antagonist GR32191 to remove secondary TPαR feedback mechanisms. 
Whilst indomethacin caused almost complete ablation of both collagen and arachidonic acid 
induced platelet TxB2 generation AZD1208 did not cause any significant alterations in TxB2 
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generation indicating it does not regulate COX-1 activity (Figure 5A). In further support of 
AZD1208 mediating its inhibitory actions via inhibition of TPαR receptor signalling and not 
inhibition of cyclooxygenase activity, whilst AZD1208 causes inhibition of U46619 mediated 
platelet aggregation, concentrations of indomethacin that cause ablation of platelet responses 
to arachidonic acid, are unable to inhibit platelet activation by TPαR agonist U46619 (Figure 
5A).  
Pim kinase inhibitors reduce signalling events downstream of TPαR  
The TPαR receptor is coupled to both Gq and Gα13 proteins. Gq couples the TPαR to 
phospholipase Cβ which in turn regulates calcium mobilisation and the activation of Protein 
kinase C (PKC), key mediators of granule secretion and activation of integrin αIIbβ3. Gα13 
regulates the Rho/Rho-kinase signalling pathway which regulates the phosphorylation of 
myosin IIa and is important for the regulation of cytoskeletal rearrangements and platelet 
shape change. 
To determine whether Pim kinase regulates processes downstream of TPαR coupled G 
proteins, levels of intracellular calcium, PKC activity and myosin light chain (MLC) 
phosphorylation were monitored following stimulation with U46619. As shown in figure 5B, 
treatment of platelets with AZD1208 caused a significant reduction in calcium mobilisation 
following stimulation with U46619 (0.3 µM) compared to vehicle control treated platelets. In 
contrast no significant difference in calcium mobilisation was observed following stimulation 
with ADP (10 µM) supporting a specific role for Pim kinase in the regulation of TPαR signalling. 
AZD1208 also caused a reduction both in PKC activity and MLC (S19) phosphorylation 
compared to vehicle controls following stimulation with U46619 (1µM) (Figure 5C and D). Gα13 
is also associated with the regulation of integrin αIIbβ3 outside in signalling 25. Phosphorylation 
of Y773 on the integrin β3 tail which is essential for propagation of outside-in signalling was 
reduced in U46619 stimulated platelets pretreated with AZD1208 compared to vehicle treated 
control platelets (Figure 5E). Taken together these results support a role for Pim kinase in the 
positive regulation of Gq and Gα13  signalling downstream of TPαR activation. 
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AZD1208 is not a competitive antagonist of the TPαR 
As components of both Gq and G13 signalling, pathways immediately downstream of TPαR 
activation, were found to be inhibited following treatment with AZD1208 we hypothesised that 
it was having direct effect on the function of the TPαR itself. One potential mechanism of action 
could be that Pim kinase inhibitors such as AZD1208 act as antagonists of the TPαR and 
inhibit the TPαR directly, independent of Pim kinase. To determine whether AZD1208 acts as 
a competitive TPαR antagonist, platelet aggregation was measured following treatment with 
increasing concentrations of AZD1208 and stimulation with a range of U46619 concentrations 
so that the concentration relationship between inhibitor and antagonist could be quantified by 
Schild analysis. As shown in Figure 6A the inhibitory effect of AZD1208 became saturated by 
10 µM, with higher concentrations (30, 50, 100 µM) unable to achieve greater levels of 
inhibition. In contrast, increasing concentrations of competitive TPαR antagonist GR32191 
(Figure 5) caused non-saturable inhibition of aggregation stimulated by U46619 and 
generated a linear Schild plot with a pA2 of 8.9 which was consistent with the reported 
properties of this competitive antagonist acting at the TPαR 26 . In contrast, the Schild plot for 
AZD1208 was linear up to a concentration of 10 µM at which point the inhibitory effects were 
saturated and increasing concentrations AZD1208 no longer altered the apparent EC50 of 
U46619. These results indicate that the concentration-response relationship of GR32191 and 
U46619 in the aggregation assay was consistent with that of a TP receptor agonist and 
antagonist competing to bind to the orthosteric site, while the results with AZD1208 do not 
conform to this model. 
AZD1208 alters TPαR receptor surface expression  
It has been described previously that Pim kinase modulates levels of the CXCR4 receptor at 
the surface of CLL cells 18,19. We hypothesised that Pim kinase inhibitors could modulate TPαR 
function via a similar mechanism in platelets and measured expression levels of TPαR 
following treatment with AZD1208 using flow cytometry to investigate this further. A TPαR 
antibody that recognises the N-terminal (extracellular) region of the TPαR was used to 
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determine surface expression levels of TPαR on platelets (Figure 6C). As previously described 
27 stimulation of platelets with U46619 was associated with a reduction in cell surface levels 
of TPαR compared to unstimulated platelets due to receptor internalisation. Resting platelets 
treated with AZD1208 (10 μM) showed reduced surface levels of the TPαR receptor compared 
to vehicle treated controls with total levels of TPαR unaffected by AZD1208 treatment. U46619 
(1 μM) stimulated platelets pretreated with AZD1208 also showed reduced surface expression 
levels of TPαR compared to vehicle treated controls and also compared platelets treated with 
U46619 only. These findings indicate that reduced U46619 signalling following treatment with 
AZD1208 is linked to reduced surface expression levels of TPαR.  
AZD1208 inhibits CXCR4 signalling in human platelets 
CXCR4 is expressed in platelets and is able to signal following stimulation with its ligand SDF-
1α 28-30. To determine whether inhibition of Pim kinase alters CXCR4 signalling in human 
platelets, aggregometry following stimulation with SDF-1α was performed in vehicle and 
AZD1208 treated human PRP, 200 ng/mL SDF-1α caused a modest level of platelet 
aggregation (~50%) in vehicle treated platelets which was significantly reduced in AZD1208 
(100 µM) treated samples (~20% aggregation) (Figure 6D). These observations indicate that 
in addition to regulation of the TPαR, Pim kinase also regulates platelet CXCR4 receptor 
function.  
DISCUSSION 
Development of kinase inhibitors as potential therapeutics for solid tumours and 
haematological malignancies has been fuelled by the recent successes of kinase inhibitor 
therapy for cancers 1,2,31,32. Pim kinase is known to enhance cancer progression and drug 
resistance, and loss of all three Pim kinase isoforms does not affect embryo viability, indicating 
inhibition of Pim activity is likely to be tolerable 10,11,33. In addition to its well established role in 
the regulation of cycle progression and prevention of cellular apoptosis 3-6,23, it has also been 
shown to play roles in cell migration, potentially contributing to metastasis and cell invasion 
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18,19 and is also implicated in drug resistance through activation of multi-drug resistance 
transporters 7-9. Pim kinase and is therefore seen as a promising potential drug target. 
Pim kinases have been shown to be highly expressed in hematopoietic cells with important 
roles in the development and differentiation of megakaryocytes 10 and platelets 11 15. Deletion 
Pim-1 alone has no effect on the hematopoietic system 16, possibly indicating a level of 
redundancy between the Pim kinase family members. Kinases often have broad expression 
profiles across several different cell types which increases the risk of kinase inhibitors having 
unwanted side effects. Platelets in particular rely heavily on kinase driven signalling cascades 
to enable them to function effectively in response to vascular damage. Several kinase 
inhibitors have been reported that affect the ability of platelets to activate and are associated 
with an increased risk of bleeding 34 35,36. 
Western blot analysis identified expression of both the 44 kDa and 32 kDa variants of Pim-1 
kinase in human and mouse platelets. Whilst Pim-2 and Pim-3 were not identified in our 
assays, expression of either paralog in human and mouse platelets cannot be ruled out. 
Comparison of thrombus formation on collagen under flow in vitro established that platelets 
from Pim-1 deficient mice showed significant attenuation in comparison to wild type control, 
highlighting a role for Pim-1 kinase in the regulation of platelet function and thrombus formation 
under arterial flow on collagen. Despite the reduction in thrombotic potential, deletion of Pim-
1 was not associated with altered haemostasis, indicating that drugs targeting Pim kinase 
activity could offer an anti-thrombotic therapeutic strategy that is not associated with increased 
bleeding risk usually observed with other anti-platelet agents.  
In support of the anti-thrombotic potential of Pim kinase inhibitors we determined that several 
structurally different Pim kinase inhibitors AZD1208, PIM-447, SGI-1776, SMI-4a and 
CX6258, which are pan-Pim kinase inhibitors that target all three Pim kinases, all caused 
inhibition of platelet functional responses, including aggregation to GPVI agonists collagen 
and CRP-XL, CXCR4 ligand SDF-1α (CXCL12) and TxA2 mimetic U46619, but not to other 
GPCR agonists including thrombin, TRAP6 or ADP, with an inhibitory profile similar to that 
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observed by Lordkipanidzé et al in a patient with a mutation in the TP receptor 27,37. 
Furthermore inhibition of collagen induced platelet responses was found to be due to an 
inhibition of TPαR signalling as the level of platelet aggregation observed in the presence of 
indomethacin or TPαR antagonist GR32191 was not further decreased following treatment 
with AZD1208 (10µM).  Similar to the reduced thrombus formation observed in whole blood 
from Pim-1 deficient mice, AZD1208 caused significant attenuation of thrombus formation on 
collagen under flow in vitro under arterial and pathological shear rates and dramatic inhibition 
of thrombus formation in vivo (Figure 2). Interestingly however, no effect on platelet adhesion 
and thrombus formation at venous flow rates was observed following treatment with AZD1208, 
this combined with the lack of effect on bleeding in mice following damage to the tail vein, 
suggests that although Pim kinase inhibition or deficiency reduces thrombus formation under 
high arterial shear, this does not alter thrombus formation or haemostasis at venous or low 
shear. This absence of effect is likely due to the lack of inhibition of PAR or P2Y receptor 
mediated platelet activation by Pim kinase inhibitors. Previous studies have shown that whilst 
GPVI deficiency or inhibition has varying effects in tail bleeding assays38 39, PAR or P2Y12 
deficiency or P2Y1 inhibition results in significant increases in tail bleeding and alteration of 
haemostasis in mice 39-41. As initial adhesion to collagen is unaffected following treatment with 
AZD1208, maintenance of PAR and P2Y receptor responses may compensate for the lack of 
TP receptor signalling allowing for normal haemostasis.  The lack of bleeding effect following 
treatment with AZD1208 is consistent with the lack of reported bleeding related adverse effects 
in patients in a recent phase 1 clinical study investigating the efficacy of AZD1208 in solid and 
haematological cancers 24. This provides further evidence that Pim kinase inhibitors may not 
be associated with drug induced platelet dysfunction related bleeding events and points to 
future use of Pim kinase inhibitors as a possible treatment strategy for individuals with 
increased risk of CVD and atherosclerosis, conditions associated with pathological shear 
rates. 
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Investigation into how Pim kinases elicit their inhibitory effects on TPαR signalling, revealed 
that AZD1208 inhibited TPαR downstream signalling events pointing to upstream regulation 
of TPαR signalling most likely via direct regulation of the TPαR. It has previously been 
described that Pim- 1 kinase regulates CXCR4 activity in Jurkat and CLL cells via regulation 
of receptor surface expression levels of the receptor 18,19. Inhibition or deletion of Pim kinase 
reduces surface expression levels of CXCR4 and inhibits CXCL12/SDF-1 signalling 29,30.  
Similarly, in our study we identified reduced surface expression levels of the TPαR in platelets 
following treatment with AZD1208 compared to vehicle treated controls.  
The TPαR signalling pathway is a key target to reduce CVD related thrombotic events and 
inflammation in patients. Despite widespread use, currently available GPCR targeted 
therapies are associated with variable patient outcomes and adverse side effects. Aspirin is 
the ‘gold standard’ anti-platelet agent for the prevention of arterial thrombosis. Aspirin targets 
platelet TPαR signalling via an indirect route, by inhibiting COX-1, the enzyme that controls 
synthesis of TxA2. Aspirin however, has dose-limiting off-target effects on COX-2, an enzyme 
involved in synthesis of endogenous inhibitors of platelet function that can increase the risk of 
thrombosis when repressed. Aspirin is also less effective in patients suffering from diabetes, 
hypertension and obesity, and is associated with increased severe bleeding risk 42 with one 
recent meta-analyses suggesting that in low risk individuals the harms of aspirin outweighs 
the cardiovascular benefits 43,44 45.Our findings suggest that Pim kinases may be a safer target 
to control thrombosis. 
The mechanism underlying the regulation of TPαR signalling by Pim-1 kinase requires further 
investigation. In other cell types the 44 kDa variant of Pim-1 kinase, Pim-1L is localised to the 
plasma membrane and associated with the phosphorylation and regulation of several 
membrane proteins, whilst the smaller 32 kDa variant Pim-1S predominantly localises to the 
cytosol and nucleus 7,46. One possibility is that Pim kinase phosphorylates the TPαR controlling 
its surface expression levels, similar to the mechanism observed for CXCR4 in CLL cells. 
Sequence alignments of the Pim kinase substrate recognition sequence have identified 4 
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putative Pim kinase phosphorylation sites within the TPαR sequence including one within the 
first intracellular loop, a region that has previously been shown to be associated with TPαR 
surface expression and receptor function 27. Pim kinase inhibition may therefore disrupt 
phosphorylation of the receptor and reduce surface expression via increasing its 
internalisation or preventing the dynamic process of receptor recycling to the surface. It is also 
possible that Pim kinase does not phosphorylate the receptor directly and instead orchestrates 
interaction with other proteins that regulate receptor surface expression 18,19.  
This work identifies a novel, Pim kinase dependent regulatory mechanism for the TPαR and 
represents a new targeting strategy that is independent of COX-1 inhibition or direct 
antagonism of the TPαR that whilst reducing thrombosis does not increase the risk of bleeding.  
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FIGURE LEGENDS 
Figure 1. Expression of Pim kinase in human and mouse platelets. A i) HaemAtlas 
analysis of Pim kinase mRNA expression levels. Pim kinase mRNA levels were quantified in 
human megakaryocytes and a range of blood cells by analysis of gene array data. 
Megakaryocytes (MK), human erythroblasts (EB), HUVEC cells, monocytes (CD14), 
granulocytes (CD66), mature B cells (CD19), natural killer cells (CD56), cytotoxic T cells (CD*) 
and helper T cells (CD4), 10+ (lighter colour) was deemed high expression. B) Human and 
mouse washed platelets (three preparations) were lysed in SDS PAGE Laemmli sample 
buffer, separated on SDS PAGE gels and transferred to PVDF membranes before blotting 
with anti-Pim-1 antibody. K562 and Jurkat cell lysates were included as positive controls. Actin 
was included as a loading control. Representative blots shown.  
Figure 2. Genetic deletion and pharmacological inhibition of Pim-1 kinase attenuates 
thrombus formation on collagen, but does not cause bleeding. A) DiOC6 loaded mouse 
whole blood from Pim1+/- (black) or Pim1-/- (red) mice was perfused through collagen coated 
(100 µg/mL) Vena8Biochips at a shear rate of 1500 s-1. i) Representative images taken at the 
end of recording shown. ii) Thrombus formation was determined after 4 minutes by comparing 
% area covered.  B) Tail bleeding in Pim-1+/- or Pim-1-/- mice represented as time to cessation 
of bleeding (secs). C, D and E) DiOC6 loaded human whole blood was pretreated with vehicle 
(black) or 100 µM AZD1208 (red) for 10 minutes before perfusion through collagen coated 
(100 µg/mL) Vena8Biochips at a C) arterial shear rate of 20 dyn/cm2, D) pathological shear 
rate of 135 dyn/cm2 or E) venous shear rate of 4.5 dyn cm2, 100µM AZD1208 was chosen due 
to reduced bioavailability of AZD1208 in plasma. Thrombus formation was determined after 5 
(pathological shear) or 10 (arterial and venous) minutes by comparing % max vehicle 
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fluorescence intensity, which measures both surface area coverage and thrombus size, in the 
vehicle and treated samples. i) Representative images taken at the end of recording shown. 
ii) Data expressed as % max vehicle fluorescence intensity. F) Thrombus formation was 
determined in vivo following FeCl3 injury in mice pretreated for 10 mins with vehicle or 100 
µM AZD1208, DiOC6 used to enable visualisation of platelets, i) representativs images taken 
at 0,. 300, 600 and 900 secs, ii) Data expressed as time to occlusion (secs). (G) Tail bleeding 
determined as time to cessation of bleeding (secs) in mice pretreated with vehicle or 100 µM 
AZD1208 for 10 minutes. Results are mean ± S.E.M. for n≥3, * indicates p≤0.05 **  indicates 
p≤0.01 **** indicates p≤0.001 in comparison to vehicle control, where normalised data shown, 
statistics were performed prior to normalisation. 
Figure 3. AZD1208 inhibits platelet aggregation. Washed human platelets were pre-treated 
with increasing concentrations of AZD1208 (0.1, 1, 10 µM) prior to stimulation with either A) 
Collagen (1 µg/mL), B) CRP-XL (0.3 µg/mL), C) U46619 (0.3 µM), D) Thrombin (0.03 U/mL) 
and E) ADP (10 µM) and aggregation monitored using optical light transmission aggregometry, 
i) Representative traces and ii) quantified data shown. iii) Human washed platelets were pre-
treated with 10 µM AZD1208 (red) or vehicle (black) prior to stimulation with A) collagen (0.01-
10 µg/mL), B) CRP-XL (1-3 µg/mL), C) U46619 (3 nM- 3µM), D) Thrombin (0.01-1 U/mL) or 
E) ADP (0.1-100 µM) and aggregation was monitored after 5 minutes using an optical light 
transmission plate based aggregometry assay, quantified data shown. Results are mean ± 
S.E.M. for n≥3, * indicates p≤0.05 *** indicates p≤0.005 in comparison to vehicle control; 
where normalised data shown, statistics were performed prior to normalisation. 
Figure 4. Inhibition of thromboxane A2 signalling underlies inhibition of collagen 
induced aggregation and thrombus formation by Pim kinase inhibitors. Human washed 
platelets were treated with A) increasing concentrations of AZD1208 (1-100 µM) or vehicle 
control prior to stimulation with increasing concentrations of U46619 (0.03 – 10 µM). B) 10 µM 
AZD1208 in the presence or absence of A) indomethacin (10 µM) or B) TxA2 receptor 
antagonist GR32191 (100 nM) and aggregation monitored after 5 minutes of stimulation by 
collagen (0.01-10 µg/mL) using a 96 well plate based aggregometry assay. C) DiOC6 loaded 
human whole blood was pretreated with vehicle (black) or 100 µM AZD1208 (red), in the 
presence of 10 µM indomethacin for 10 minutes before perfusion through collagen coated 
(100 µg/mL) Vena8Biochips at a shear rate of 20 dyn/cm2. Thrombus formation was 
determined over 10 minutes by comparing fluorescence intensity in the vehicle and treated 
samples. i) Representative images taken at 10 minutes shown. ii) Data expressed as % max 
vehicle fluorescence and normalised to an untreated (no indomethacin treatment) control, 
where the maximum fluorescence observed in untreated platelets is considered to be 100% 
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thrombus formation. D) Fibrinogen binding in mouse washed platelets from control (Pim1 +/-)  
or Pim1-/- mice was determined following stimulation with Thrombin (0.01 U/mL), U46619 (10 
µM) and CRP (10 µg/mL) and expressed as % positive cells. Results are mean + S.E.M. for 
n≥3, * indicates p≤0.05  ***p≤0.005 in comparison to vehicle control; where normalised data 
shown, statistics were performed prior to normalisation. 
Figure 5. AZD1208 inhibits TP receptor signalling. Resting and stimulated human washed 
platelets were treated with 10 µM AZD1208 for 10 minutes and A) stimulated with i) collagen 
(1 µg/mL) or arachidonic acid (1 mM) or ii) U46619 (0-3µM) in the presence and absence of 
indomethacin (10 µM) and i) TxB2 levels (EnzoLife sciences ELISA) or ii) aggregation 
monitored after five minutes of shaking. B) Mobilisation of intracellular calcium was determined 
in FURA-2 AM loaded platelets following stimulation with U46619 (300 nM) or ADP (10 µM) i) 
Representative traces and ii) quantified data shown and data expressed as the change in 
[Ca2+] (nM) C-E) Human platelets were pre-incubated with vehicle or AZD1208 (10 µM) for 10 
minutes and stimulated with U46619 (1 µM) for 30 secs or 3 minutes before lysis in SDS 
Laemmli sample buffer C) PKC activity was determined by blotting these samples and using 
a phospho-site specific antibody (for the PKC substrate recognition sequence) which detects 
PKC substrate phosphorylation and D) myosin light chain phosphorylation at Ser19 using a 
phospho-specific antibody (that recognises the phosphorylated myosin light chain). E) 
phosphorylation of the integrin β3 subunit at Y773 using a phospho-specific antibody. Actin 
was used to confirm equal loading. i) representative blots and ii) quantified data shown. Levels 
of total phosphorylation were quantified and expressed as a percentage of the maximum 
phosphorylation observed in vehicle treated stimulated controls. Results are mean + S.E.M. 
for n≥3, * indicates p≤0.05 in comparison to vehicle controls.  
Figure 6. AZD1208 reduces TPαR surface expression and signalling and does not act 
as a competitive antagonist of the TPαR. Human washed platelets were pre-treated with A) 
AZD1208 (1, 3, 10, 30, 50 and 100 µM) or B) GR32191 (1, 2, 3, 5, 10, 30, 100 nM) prior to 
stimulation with U46619 (3 nM- 3µM) and aggregation was monitored after 5 minutes using 
an optical light transmission plate based aggregometry assay, quantified data shown. i) 
percentage aggregation. ii) EC50 values from the aggregation dose response curves 
determined following incubation with AZD1208 were used to plot a Schild regression plot to 
determine whether AZD1208 acts as an antagonist for the TxA2 receptor. C) AZD1208 (10 
μM; 10 mins) or vehicle control and ii) surface expression of TPαR was assessed using an 
antibody that recognises the extracellular portion of the TPαR and detected by flow cytometry. 
Samples were diluted in HBS and not fixed to avoid disruption of the membrane. Anti-DOK6 
antibody was included as a negative control. i) shows a representative histogram from the flow 
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cytometer. ii) Data expressed as a median fluorescent intensity.  iii) Total cellular TPαR was 
detected by western blotting. D) Human PRP was pre-treated with AZD1208 (100 µM) or 
vehicle control for 10 minutes prior to stimulation with SDF-1α (200 ng/mL) and aggregation 
monitored using optical light transmission aggregometry for 5 minutes. i) Representative trace 
and ii) quantified data shown. Results are mean + S.E.M. for n≥3, * indicates p≤0.05 ** 
indicates p≤0.01  *** indicates p≤0.005 in comparison to vehicle control, where normalised 
data shown, statistics were performed prior to normalisation. 
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Anti-platelet properties of Pim kinase inhibition is mediated through disruption of 
thromboxane A2 receptor signalling.  
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MATERIALS AND METHODS 
 
Reagents 
AZD1208, CX-6258, LGH447, SGI-1776 and SMI-4a were purchased from SelleckChem. 
U46619 was purchased from Enzo Life Sciences (Exeter, UK). Bovine thrombin and ADP were 
purchased from Sigma Aldrich (Poole, UK). Horm collagen was purchased from Nycomed, 
Austria, CRP-XL from Prof. R Farndale (University of Cambridge, UK). Primary anti- TxA2R 
(P20), Pim-1 and actin (C11) antibodies were purchased from Santa Cruz Biotechnology 
(Calne, UK). Primary antibodies for Pim-1, Pim-2 and Pim-3 (cat. Log #9779), anti-Phospho–
PKC substrate antibody (#2261), Caspase-3 (#9662), cleaved caspase 3 (#9661) and 
phospho-Ser19 Myosin light chain (#3671) antibodies were purchased from New England 
Biosciences (Cell Signalling Hitchin, UK), anti-phospho-Ser 4A4 antibody was purchased from 
Millipore (Watford, UK), anti-TP receptor (ab137607) and DOK6 (ab72730) antibodies were 
purchased from Abcam (Cambridge, UK).  Fluorophore conjugated secondary antibodies, 
Fluo-4 calcium indicator dye and Alexa-488 conjugated phalloidin were purchased from Life 
Technologies (Paisley, UK). All other reagents were from previously described sources.  
 
Mice 
Global Pim1–/– mice were described previously 1,2. Genotyping was confirmed by PCR of tail 
tissue DNA using primers: AAGCACGTGGAGAAGGACCG (WT forward), 
GACTGTGTCCTTGAGCAGCG (WT reverse; Pim1+ 487bp), and 
CGTCCTGCAGTTCATTCAGG (Neo reverse; Pim1– ~360bp). Due to breeding strategy age 
and litter matched Pim-1+/- mice were used as controls. Pim-1+/- mice were found to show no 
difference in platelet function to C57BL/6 WT mice (data not shown). Mice used were C57BL/6 
of both sexes, aged 7-10 weeks, and were treated according to the National Institutes of 
Health and Medical College of Wisconsin Institutional Animal Care and Use Committee 
guidelines and following procedures approved by the University of Reading Research Ethics 
Committee.  
 
Platelet preparation 
For mouse experiments, blood was collected by mouse retro-orbital plexus bleeding and was 
anticoagulated in acid-citrate-dextrose 3. Platelet-rich plasma was obtained by centrifugation 
of the blood at 100 g for 8 min, followed by centrifugation of the supernatant and buffy coat at 
100 g for 6 min. After washing twice in washing buffer (140 mM NaCl, 5 mM KCl, 12 mM 
trisodium citrate, 10 mM glucose, and 12.5 mM sucrose, pH 6.0), platelets were resuspended 
at 4 x 108 platelets/ml in resuspension buffer (140 mM NaCl, 3 mM KCl, 0.5 mM MgCl2, 5 mM 
NaHCO3, 10 mM glucose, 10 mM HEPES, pH 7.4) and were allowed to rest for 30 min before 
use. 
For human experiments, blood was obtained from consenting aspirin-free healthy volunteers 
following procedures approved by the University of Reading Research Ethics Committee.  
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Blood was collected into 4% (w/v) sodium citrate and then mixed with acid citrate dextrose 
(29.9 mM trisodium citrate, 113.8 mM glucose and 2.9 mM citric acid [pH 6.4]) if washed 
platelets were prepared. Platelet rich plasma (PRP) was prepared by centrifugation at 100 g 
for 20 minutes at room temperature. ADP sensitive washed platelets were prepared from PRP 
(containing ACD) by centrifugation at 350 g for 20 minutes followed by resuspension in 
modified Tyrode’s-HEPES buffer (134mM NaCl, 0.34mM Na2HPO4, 2.9mM KCl, 12mM 
NaHCO3, 20mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 5mM glucose and 1mM 
MgCl2, pH 7.3) and used immediately. 
 
Thrombus formation on collagen under flow in vitro 
Thrombus formation on and platelet interaction with immobilized type I collagen was 
performed as described previously 4 using the VenaFlux Platform and Vena8Fluor+ Biochips 
(Cellix) 5. Channels were coated overnight at 4°C with collagen, then blocked with 1% 
BSA/PBS for 1 h and replaced with PBS. Mouse blood was collected by retro-orbital plexus 
bleeding and was anticoagulated in 25 mM PPACK. Human blood was collected into sodium 
citrate (4% w/v). Platelets in whole blood were incubated with 10 mM DiOC6 (Thermo Fischer 
Scientific) for 10 min. Perfusion was performed for either 4 min (mouse) or 12 minutes (human) 
at 37°C with an arterial shear rate of 1500 s-1. For mouse, platelet adhesion to the collagen-
coated chip was monitored with an Axioscope A.1 Inverted Microscope (Carl Zeiss) at 20x 
magnification through a Digital CCD Camera C10600-10B (Hamamatsu Photonics). Human 
thrombus formation was visualised using a 20 x magnification lens on a Nikon A1-R confocal 
microscope.  Images were brightness corrected and converted to a binary mask with software 
provided auto-thresholds. Binary Mask Particles were then analysed to determine thrombus 
count and surface area. 
 
 
FeCl3 injury thrombosis model 
Male C57BL/6 mice (8 – 10 weeks of age) were anesthetized through an intraperitoneal. 
injection of ketamine (100 mg/kg), metedor (20 mg/kg) and atropine (0.25 mg/kg) and injected 
with DIOC6 to fluorescently label platelets (0.28 µL of a 1mg/mL solution per body weight). 
AZD1208 (0.16 µL of a 100 mM solution per body weight) or vehicle control were injected 
immediately before isolation of mesenteric arteries. Vascular injury was induced by applying 
a 1 mm2 Whatmann filter paper saturated with 10% FeCl3 for 90 seconds and images recorded 
for at least 20 minutes. Images were acquired using a Hamamatsu digital camera C9300 
(Hamamatsu Photonics UK Ltd) and Olympus BX61W1 microscope (Olympus Imaging Ltd, 
UK) and analysed using Slidebook5 (Intelligent Imaging Innovations, USA).  
 
Tail bleeding 
Bleeding time in Pim-1-/- and Pim-1+/- mice was determined by transecting 2 mm of distal 
mouse tail and immediately immersing the tail in 37°C isotonic saline 3. A complete cessation 
of bleeding was defined as the bleeding time. Measurements exceeding 10 min were stopped 
by cauterization of the tail. 
Tail bleeding experiments with Pim kinase inhibitors were performed on 20–35 g male mice, 
anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) injected intraperitoneally. 
AZD1208 (100 µM) or vehicle control (DMSO 0.1% v/v) was injected into the femoral vein 10 
minutes prior to removal of the tip of the tail. The tail tip was then placed in sterile saline (37 
ºC) and time to cessation of bleeding (secs) measured.  
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Platelet aggregation  
Aggregation of human washed platelets was measured by optical aggregometry (Helena 
Biosciences, Gateshead, UK) as described previously 6. Endpoint aggregation measurements 
were also taken using a plate based assay in which PRP or washed platelets at a 
concentration of 4x108 cells/ml were loaded onto 96-well half-area plates (Greiner) and treated 
with inhibitors or vehicle for 10 mins at 37o C prior to addition of agonist. Plates were shaken 
at 1,200 rpm for 5 mins at 37o C using a plate shaker (Quantifoil Instruments) and absorption 
of 405 nm light measured using a NOVOstar plate reader (BMG Labtech).  
 
Alpha granule secretion and fibrinogen binding by flow cytometry 
Flow cytometry was used to examine alpha granule secretion and affinity up-regulation of the 
integrin αIIbβ3 by detecting levels of P-selectin exposure and fibrinogen binding respectively . 
Following inhibitor or vehicle treatment for 10 minutes and stimulation with U46619, platelets 
were incubated at room temperature for 20 minutes with PE/Cy5 anti-human CD62P (P-
selectin) and fluorescein isothiocyanate-labelled (FITC) anti-fibrinogen antibody. Reactions 
were stopped and platelets fixed by addition of 0.2% (v/v) paraformaldehyde. Data for 5000 
events were collected using a BD Accuri C6 flow cytometer and analysed using the CFlow 
Sampler software as described previously 4.   
 
 
TxB2 generation assay 
PRP was stimulated with either 3 µg/mL Collagen or 100 µM Arachidonic acid, both in the 
presence and absence of 100 μM AZD1208 or indomethacin (10 µM) at 37 °C with shaking at 
1200 rpm on a plate shaker. The reaction was stopped after 5 min by the addition of 50 μM 
indomethacin and 2 mM EDTA, and the cell debris removed by centrifugation. Samples were 
diluted 1/100 in assay buffer provided prior to testing. The TxB2 assay was performed using 
an assay kit (Enzo Life Sciences (UK) Ltd, Exeter UK) according to the manufacturer's 
specification and the 96-well ELISA plate read on a FlexStation microplate reader (Molecular 
Devices). Data analysis was subsequently conducted using a standard curve constructed from 
a serial dilution of working standard samples to calculate TxB2 production. 
 
Mobilisation of intracellular calcium 
PRP was loaded with Fura-2 AM (2 µM) for 1h at 30oC and then washed by centrifugation at 
350 g for 20 mins and resuspended in Tyrode’s-HEPES buffer containing 0.4 U/ml apyrase. 
Fura-2 loaded platelets were incubated with inhibitors or vehicle at 37oC prior to addition of 
agonists. Fluorescence measurements with excitation at 340 and 380 nm and emission at 510 
nm were recorded over a period of 5 mins using a NOVOstar plate reader (BMG Labtech). 
[Ca2+]i  was estimated using the ratio of the 340 and 380 nm excited signals and the method 
of Grynkiewicz et al was utilised 7. The maximum fluorescence ratio was measured following 
treatment with 50 µM digitonin and the minimum fluorescence ratio measured following 
treatment with 10 mM EGTA. Autofluorescence was also corrected for, using platelets which 
had not been loaded with Fura-2. [Ca2+]i concentrations were calculated as described 
previously 8,9. 
 
Immunoblotting and immunoprecipitation 
Washed platelets (4 × 108 cells/mL) were lysed in an equal volume of NP40 buffer (300 mM 
NaCl, 20 mM Tris base, 2 mM EGTA, 2 mM EDTA, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml 
leupeptin, 0.7 µg/ml pepstatin A, 2 mM sodium orthovanadate, 2% NP-40, pH 7.3) for lysate 
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preparation for immunoprecipitation or lysed with 6 x Laemlli sample buffer for directanalysis 
by western blotting. For immunoprecipitation proteins of interest were isolated using 1 μg of 
appropriate antibodies as described previously 6. Immunoblotting was performed using 
standard techniques as described previously 10.  
Proteins were detected using fluorophore conjugated secondary antibodies and visualised 
using a Typhoon Fluorimager and Image Quant software (GE Healthcare). Band intensities 
were quantified and levels of the immunoprecipitated protein were used to normalize the 
phosphorylation data using Image Quant software. 
 
Surface expression of TPαR by flow cytometry 
Flow cytometry was used to determine surface expression levels of the TP receptor. Following 
inhibitor or vehicle treatment for 10 minutes and stimulation by U46619. Platelets were 
incubated at room temperature for 20 minutes with anti-human TP receptor (Abcam) that 
recognises the extracellular portion of the TP receptor and Alexa647 conjugated anti-rabbit 
secondary antibody. Anti-DOK6 antibody (Abcam) was used as a negative control. Reactions 
were stopped by dilution in HEPES- buffered saline and analysed immediately. Data for 
10,000 events were acquired using a BD Accuri C6 flow cytometer and analysed using the 
CFlow Sampler software. 
 
Statistics 
All experiments were performed at least in triplicate. Statistical analyses of the data were 
carried out using GraphPad prism software. When comparing two sets of data, an unpaired, 
2-tailed Student’s t test (simple) statistical analysis was used. If more than two means were 
present, significance was determined by one-way or two-way ANOVA followed by Bonferroni 
correction (multiple) or the Kaplan-Meier analysis (time-to-event). Where data was 
normalised, statistical analysis was performed prior to normalisation and also using the non-
parametric Wilcoxon signed-rank test. P≤0.05 was considered statistically significant. Unless 
stated otherwise, values were expressed as mean ±SEM. 
 
Study approval 
For experiments using human blood, procedures and experiments were approved by the 
University of Reading and Manchester Metropolitan University Research Ethics Committees.   
Mice used were treated according to the National Institutes of Health and Medical College of 
Wisconsin Institutional Animal Care and Use Committee guidelines and as following 
procedures approved by the University of Reading Research Ethics Committee. 
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SUPPLEMENTAL DATA 
 
 
Supplemental Figure 1. Expression of Pim kinase in human megakaryocytes and 
platelets. RNA seq analysis of A) Pim-1, B) Pim-2 and C) Pim-3 mRNA-seq expression in 
megakaryocytes and platelets from 5 different data sets, taken from the HAEMGEN Tools 
portal Expressed! https://haemgen.haem.cam.ac.uk/expressed 
 
 
 
 
 
 
Supplemental Figure 2. Pim-1-/- deficient platelets have normal receptor expression 
levels. A) Global Pim1–/– mice genotyping was confirmed by PCR of tail tissue DNA using 
primers: AAGCACGTGGAGAAGGACCG (WT forward), GACTGTGTCCTTGAGCAGCG (WT 
reverse; Pim1+ 487bp), and CGTCCTGCAGTTCATTCAGG (Neo reverse; Pim1– ~360bp). B) 
Expression levels of different platelet surface receptors, GPIba, GPIbb, GPIX, GPV, Beta1, 
Beta3 and GPVI were determined by flow cytometry in platelets from Pim-1+/- and Pim-1-/- 
mice. Results are mean ± S.E.M. for n≥3, * indicates p<0.05 in comparison to controls.  
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Supplemental Figure 3. Pim kinase inhibition does not alter adhesion to collagen.  . 
Human washed platelets pretreated with 10 µM AZD1208 or vehicle control were exposed to 
collagen (100 µg/mL) coated coverslips and left to adhere and spread for 1 hour at room 
temperature. A) Adhesion, number of platelets adhered were counted in 5 randomly selected 
fields of view and expressed as the average number of cells per image. B) Spreading, platelets 
were classified into 3 different categories to determine the extent of their spreading (Adhered 
but not spread, Filopodia: platelets in the process of extending filopodia and Lamellipodia: 
platelets in the process of extending lamellipodia including those fully spread). Results 
expressed as relative frequency, as a percentage of the total number of platelets adhered. 
n≥3. 
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Supplemental Figure 4. Structurally distinct Pim kinase inhibitors attenuate platelet 
activation by the TP receptor. (A-C) Human washed platelets were pre-treated with different 
PIM kinase inhibitors PIM-447 (LGH-447) (10 µM) (blue) SGI-1776 (10 µM) (green), SMI-4a 
(30 µM) (purple), CX-6258 (10 µM) (orange) or vehicle control (black) prior to stimulation with 
i) U46619 (3 nM- 3µM), ii) collagen (0.01-10 µg/mL)  or iii) Thrombin (0.01-1 U/mL). (D-G) 
Human washed platelets were treated with A) 10 µM PIM447 (LGH447), B) 10 µM SGI-1776, 
C) 30 µM SMI-4a or D) 10 µM CX6258  (grey) in the presence of indomethacin prior to 
stimulation y collagen (0.01-10 µg/mL) and aggregation was monitored after 5 minutes using 
an optical light transmission plate based aggregometry assay, quantified data shown. Results 
are mean + S.E.M. for n≥3, * indicates p<0.05 in comparison to controls.  
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Supplemental Figure 5. AZD1208 does not cause apoptosis in platelets. Human washed 
platelets were treated for 2 hours with or without A) AZD1208 (10µM), SGI-1776 (10µM), SMI-
4a (30µM), ABT-263 (10 µM) or vehicle control prior to analysis by flow cytometry for Annexin 
V binding which is a measure of phosphatidylserine exposure, a marker of apoptosis. Data 
are expressed as % positive events for Annexin V. B) Platelets were incubated with AZD1208 
(10µM), SGI-1776 (10µM), SMI-4a (30µM) or CX6258 (10µM) for 2 hours and lysed in Laemmli 
sample buffer. Samples were then run on SDS PAGE gels, transferred to PVDF membrane 
before blotting for caspase-3 or cleaved caspase-3 (a marker of apoptosis). Actin was included 
as a loading control.  ABT-263 (10 µM) a Bcl-2 inhibitor and known initiator of apoptosis in 
platelets was included as a positive control. Results are mean ± S.E.M. for n≥3, * indicates 
p<0.05 in comparison to vehicle controls.  
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Supplemental Figure 6. AZD1208 attenuates alpha granule secretion and integrin αIIbβ3 
activation.  Resting and stimulated human washed platelets were treated with 10 µM 
AZD1208 prior to stimulation with A) U46619 (1 µM), B) Collagen (10 µg/mL) or C) CRP (1 
µg/mL) and i) Alpha granule secretion determined by monitoring P-selectin exposure and ii) 
Integrin activation measured as fibrinogen binding. Results are mean + S.E.M. for n≥3, * 
indicates p<0.05 in comparison to vehicle controls.  
 
 
 
 
 
 
